A wearable tag-based real-time locating system (RTLS) was much more sensitive than the smartphone-based contact tracing app TraceTogether for contact tracing, at least in a clinical setting, a local study finds.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Up to one-fifth of individuals with COVID-19 are asymptomatic, with many of them harbouring as much coronavirus as patients who are symptomatic, a study shows — raising concerns that asymptomatic carriers may drive community spread of COVID-19.
A novel once-daily fixed-dose combination (FDC) of ICS-LABA* comprising mometasone furoate and indacaterol acetate (MF-IND) is superior over an ICS monotherapy of MF in improving lung function of patients with inadequately controlled asthma, the PALLADIUM study has shown — providing another once-daily FDC option for these patients.
Commuters who had been exposed to an index case with COVID-19 during a bus journey were 42 times more likely to be infected than control riders in another bus of similar journey — adding further evidence to the notion that airborne transmission of the virus is possible, especially in an enclosed area.
The highly specific MET inhibitor capmatinib may be a new therapeutic option for patients with MET exon 14-mutated or MET-amplified non-small-cell lung cancer (NSCLC), the phase II GEOMETRY mono-1 study has shown.
More than 9 months into the combat against COVID-19, the world has seen battles being stepped up on all fronts in the search for an effective therapy. While new drugs are being developed, old drugs are repurposed as potential treatment for COVID-19, and a plethora others are upcoming in the pipeline.